个人科研网厅 | | 帮助
高级检索
当前位置： 首页 > 详情页

A Randomized Phase 3 Study of Camrelizumab plus Chemotherapy as 1st Line Therapy for Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer

| 导出 | |

文献详情

资源类型：
WOS体系：

收录情况： ◇ SCIE

作者：
Zhou, C.[1] * ; Chen, G.[2] ; Huang, Y.[3,4,5] ; Zhou, J.[6] ; Lin, L.[7] ; Feng, J.[8,9,10] ; Wang, Z.[11] ; Shu, Y.[12] ; Shi, J.[13] ; Hu, Y.[14] ; Wang, Q.[15] ; Cheng, Y.[16] ; Chen, J.[17] ; Lin, X.[18] ; Wang, Y.[19] ; Huang, J.[20,46] ; Cui, J.[21] ; Cao, L.[22] ; Liu, Y.[23] ; Zhang, Y.[24] ; Pan, Y.[22] ; Zhao, J.[25,48] ; Wang, L.[26] ; Chang, J.[27] ; Chen, Q.[28] ; Ren, X.[29] ; Zhang, W.[30] ; Fan, Y.[31] ; He, Z.[32] ; Fang, J.[33] ; Gu, K.[34] ; Dong, X.[35] ; Jin, F.[36] ; Gao, H.[37] ; An, G.[38] ; Ding, C.[39] ; Jiang, X.[40] ; Xiong, J.[30] ; Zhou, X.[41] ; Hu, S.[42] ; Lu, P.[43] ; Liu, A.[44] ; Guo, S.[45] ; Huang, J.[20,46] ; Zhu, C.[47] ; Zhao, J.[25,48] ; Gao, B.[49] ; Chen, Y.[50] ; Hu, C.[51] ; Zhang, J.[52] ; Zhang, H.[52] ; Zhao, H.[53] ; Zhou, Y.[54] ; Tai, Y.[54] ;
机构： [1]Tongji Univ, Shanghai Pulm Hosp, Dept Med Oncol, Shanghai, Peoples R China [2]Harbin Med Univ, Canc Hosp, Harbin, Heilongjiang, Peoples R China [3]Kunming Med Univ, Yunnan Canc Hosp, Kunming, Yunnan, Peoples R China [4]Kunming Med Univ, Affiliated Hosp 1, Kunming, Yunnan, Peoples R China [5]Yunnan Canc Ctr, Kunming, Yunnan, Peoples R China [6]Zhejiang Univ, Affiliated Hosp 1, Hangzhou, Zhejiang, Peoples R China [7]Guangzhou Univ Chinese Med, Affiliated Hosp 1, Guangzhou, Guangdong, Peoples R China [8]Nanjing Med Univ, Jiangsu Canc Hosp, Nanjing, Jiangsu, Peoples R China [9]Nanjing Med Univ, Jiangsu Inst Canc Res, Nanjing, Jiangsu, Peoples R China [10]Nanjing Med Univ, Affiliated Canc Hosp, Nanjing, Jiangsu, Peoples R China [11]Shandong Canc Hosp & Inst, Jinan, Shandong, Peoples R China [12]Jiangsu Prov Hosp, Nanjing, Jiangsu, Peoples R China [13]Linyi Canc Hosp, Linyi, Shandong, Peoples R China [14]Chinese Peoples Liberat Army Gen Hosp, Beijing, Peoples R China [15]Henan Canc Hosp, Zhengzhou, Henan, Peoples R China [16]Jilin Canc Hosp, Changchun, Jilin, Peoples R China [17]Hunan Canc Hosp, Changsha, Hunan, Peoples R China [18]Fujian Med Univ, Union Hosp, Fuzhou, Fujian, Peoples R China [19]Sichuan Univ, West China Hosp, Chengdu, Sichuan, Peoples R China [20]Suzhou Univ, Affiliated Hosp 1, Suzhou, Peoples R China [21]Jilin Univ, Bethune Hosp 1, Changchun, Jilin, Peoples R China [22]Univ Sci Technol China, Affiliated Hosp 1, Hefei, Anhui, Peoples R China [23]China Med Univ, Hosp 1, Shenyang, Liaoning, Peoples R China [24]Zhejiang Canc Hosp, Hangzhou, Zhejiang, Peoples R China [25]Beijing Canc Hosp, Dept Thorac Med Oncol, Beijing, Peoples R China [26]Zhengzhou Univ, Affiliated Hosp 1, Zhengzhou, Henan, Peoples R China [27]Fudan Univ, Shanghai Canc Ctr, Med Oncol, Shanghai, Peoples R China [28]Fuzhou Pulm Hosp Fujian, Fuzhou, Fujian, Peoples R China [29]Tianjin Med Univ Canc Inst & Hosp, Tianjin, Peoples R China [30]Nanchang Univ, Affiliated Hosp 1, Nanchang, Jiangxi, Peoples R China [31]Zhejiang Canc Hosp, Dept Thorac Med Oncol, Hangzhou, Zhejiang, Peoples R China [32]Fujian Canc Hosp, Fuzhou, Fujian, Peoples R China [33]Beijing Canc Hosp, Beijing, Peoples R China [34]Anhui Med Univ, Affiliated Hosp 1, Hefei, Anhui, Peoples R China [35]Huazhong Univ Sci & Technol, Tongji Med Coll, Wuhan Union Hosp, Wuhai, Peoples R China [36]Afmu, Affiliated Hosp 2, Xian, Shaanxi, Peoples R China [37]Peoples Liberat Army Gen Hosp, Med Ctr 5, Beijing, Peoples R China [38]Capt Med Univ, Beijing Chaoyang Hosp, Beijing, Peoples R China [39]Hebei Med Univ, Clin Med Coll 4, Shijiazhuang, Hebei, Peoples R China [40]First Peoples Hosp Lianyungang City, Lianyungang, Peoples R China [41]Army Med Univ, Affiliated Hosp 1, Chongqing, Peoples R China [42]Hubei Canc Hosp, Wuhan, Hubei, Peoples R China [43]Xinxiang Med Univ, Affiliated Hosp 1, Xinxiang, Henan, Peoples R China [44]Nanchang Univ, Affiliated Hosp 2, Nanchang, Jiangxi, Peoples R China [45]Chongqing Med Univ, Affiliated Hosp 1, Chongqing, Peoples R China [46]Zhejiang Univ, Affiliated Hosp 2, Hangzhou, Zhejiang, Peoples R China [47]Taizhou Hosp Zhejiang Prov, Taizhou, Peoples R China [48]Guangzhou Med Univ, Canc Ctr, Guangzhou, Guangdong, Peoples R China [49]Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Shanghai, Peoples R China [50]Jiangxi Canc Hosp, Nanchang, Jiangxi, Peoples R China [51]Cent S Univ, Xiangya Hosp, Resp Med Dept, Changsha, Hunan, Peoples R China [52]Air Force Med Univ, Affiliated Hosp 1, Xian, Shaanxi, Peoples R China [53]Anhui Med Univ, Affiliated Hosp 2, Hefei, Anhui, Peoples R China [54]Jiangsu Hengrui Med Co Ltd, Clin Res & Dev, Shanghai, Peoples R China
出处：
DOI： 10.1016/j.jtho.2019.08.425
ISSN：

关键词： Non-Squamous Non-Small Cell Lung Cancer camrelizumab phase 3

语种：
外文
被引次数：
WOS：
中科院(CAS)分区：
出版当年[2020]版：
大类 | 1 区 医学
小类 | 1 区 肿瘤学 1 区 呼吸系统
最新[2023]版：
大类 | 1 区 医学
小类 | 1 区 肿瘤学 1 区 呼吸系统
JCR分区：
出版当年[2019]版：
Q1 RESPIRATORY SYSTEM Q1 ONCOLOGY
最新[2023]版：
Q1 ONCOLOGY Q1 RESPIRATORY SYSTEM

影响因子： 最新[2023版] 最新五年平均 出版当年[2019版] 出版当年五年平均 出版前一年[2018版] 出版后一年[2020版]

第一作者：
第一作者机构： [1]Tongji Univ, Shanghai Pulm Hosp, Dept Med Oncol, Shanghai, Peoples R China
推荐引用方式(GB/T 7714)：
Zhou C.,Chen G.,Huang Y.,et al.A Randomized Phase 3 Study of Camrelizumab plus Chemotherapy as 1st Line Therapy for Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer[J].JOURNAL OF THORACIC ONCOLOGY.2019,14(10):S215-S216.doi:10.1016/j.jtho.2019.08.425.
APA：
Zhou, C.,Chen, G.,Huang, Y.,Zhou, J.,Lin, L....&Tai, Y..(2019).A Randomized Phase 3 Study of Camrelizumab plus Chemotherapy as 1st Line Therapy for Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer.JOURNAL OF THORACIC ONCOLOGY,14,(10)
MLA：
Zhou, C.,et al."A Randomized Phase 3 Study of Camrelizumab plus Chemotherapy as 1st Line Therapy for Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer".JOURNAL OF THORACIC ONCOLOGY 14..10(2019):S215-S216

相关文献

[1]非小细胞肺癌A549和H520细胞PDCD4和AP-1表达与细胞迁移的相关性研究 [2]Multi-center randomized phase II trial of pemetrexed plus oxaliplatin or pemetrexed alone as the second line treatment for stage IV non-squamous non-small cell lung cancer [3]Afatinib as first-line treatment for advanced lung squamous cell carcinoma harboring uncommon EGFR G719C and S768I co-mutation: A case report and literature review [4]Bullous pemphigoid induced by camrelizumab [5]Phase 3 Trial of Whole Brain Radiotherapy with Concurrent Erlotinib Versus WBRT Alone for NSCLC with Brain Metastases (ENTER) [6]Baricitinib in patients with rheumatoid arthritis with inadequate response to methotrexate: results from a phase 3 study [7]Galcanezumab in patients with episodic migraine: results from the open-label period of the phase 3 PERSIST study [8]Efficacy and safety of HLX01 in patients with moderate-to-severe rheumatoid arthritis despite methotrexate therapy: a phase 3 study [9]Dorzagliatin add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trial [10]Evaluation of adalimumab biosimilar candidate (HS016) in Chinese patients with active ankylosing spondylitis based on a health survey: sub-analysis of a phase 3 study.

资源点击量：56916 今日访问量：0 总访问量：1772 更新日期：2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 昆明医科大学第一附属医院 技术支持：重庆聚合科技有限公司 地址：云南省昆明市西昌路295号(650032)